The company will invest approximately €440 million to increase membrane manufacturing capacity in Carrigtwohill and to build a new manufacturing facility at Blarney Business Park, both in Cork, Ireland
Purpose-built bioconjugation facility in Lonza’s Ibex Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases
It is part of the company's CAD $30 million capital investment in the Aurora, Canada site
Wearable patch sensors (smart patches) are rising in popularity, as they offer a wide range of options for medical diagnosis
Moderna continues to expand its mRNA platform for a range of additional clinical applications and routes of administration including a modality for lung delivery
The licences will allow manufacturers from around the world to work with MPP and C-TAP to make these technologies accessible to people living in low- and middle-income countries
The capex for FY22 stood at Rs 145 crore and is expected to be in the range of Rs 250-350 crore for the entire FY23 which would be funded through a mix of internal accruals and debt
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
To lay a technological foundation for developing exosome-based medicines and cosmetic products for dermatitis treatment
Subscribe To Our Newsletter & Stay Updated
